Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy Trial)
The purpose of this phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study is to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.
Study ID: MCLA-128-CL01
Trial Phase: Phase I/II
Trial Sponsor: Merus N.V.
Therapies Used in This Trial: Zenocutuzumab